anx005
mAbexperimental
Clinical trial activity
7 trials · 7 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
5
Phase 3
2
Phase 4
0
Earliest trial started Dec 1, 2016 (NCT03010046)
Timeline
Indications
Mechanism of action
C1QA inhibitor
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Also known as
- anx005
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07020819 | Phase 3 | Jun 30, 2025 | Annexon |
| NCT04691570 | Phase 2 | Jan 31, 2021 | Annexon, Mayo Clinic |
| NCT04701164 | Phase 2/Phase 3 (Phase 3) | Dec 17, 2020 | Annexon |
| NCT04569435 | Phase 2 | Nov 15, 2020 | Annexon, Worldwide Clinical Trials |
| NCT04514367 | Phase 2 | Aug 17, 2020 | Annexon, Rocky Mountain Movement Disorders Center, Englewood, CO |
| NCT04035135 | Phase 1/Phase 2 (Phase 2) | Sep 30, 2019 | Annexon, International Center for Diarrheal Disease Research, ResearchPoint Global |
| NCT03010046 | Phase 1 | Dec 1, 2016 | Annexon, Nucleus Network Ltd |
Showing 7 of 7 trials
Page 1 / 1
Organizations
Research & Development (7)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Annexon | For profit | 7 | 7 | 3 | 2016 |
| International Center for Diarrheal Disease Research | Academic/Hospital | 1 | 0 | 1 | 2019 |
| Mayo Clinic | Academic/Hospital | 1 | 0 | 1 | 2021 |
| Nucleus Network Ltd | For profit | 1 | 0 | 1 | 2016 |
| ResearchPoint Global | For profit | 1 | 0 | 1 | 2019 |
| Rocky Mountain Movement Disorders Center, Englewood, CO | Academic/Hospital | 1 | 0 | 1 | 2020 |
| Worldwide Clinical Trials | For profit | 1 | 0 | 1 | 2020 |
7 organizations
Page 1 / 1